Gilead and Kite are plunking down big cash to get into the anti-BCMA CAR-T game.
The pair will shell out $225 million in cash upfront and $100 million in equity to Arcellx, Kite announced Friday morning, to develop the biotech’s lead CAR-T program together. Kite will handle commercialization and co-development with Arcellx, and profits in the US will be split 50-50.
Image: https://endpts.com
{iframe}https://endpts.com/gilead-arcellx-team-up-on-anti-bcma-car-t-as-biotech-touts-a-100-response-rate-at-ash22/{/iframe}